ReGenTree begins ARISE-3 trial of RGN-259 eye drops for dry eye syndrome
ReGenTree has initiated a phase 3 clinical trial, called ARISE-3, to evaluate the safety and efficacy of 0.1% RGN-259 eye drops for the treatment of ... Read More
Sun Pharmaceutical Industries gains FDA approval for CEQUA to treat dry eye disease
Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for CEQUA (cyclosporine ophthalmic solution) 0.09%, a significant advancement in ... Read More